{"schema_version":"secwatch.filing_event.v1","accession":"0001787306-24-000122","form_type":"8-K","ticker":"ARQT","cik":"0001787306","company_name":"Arcutis Biotherapeutics, Inc.","filed_at":"2024-08-14T23:59:59+00:00","discovered_at":"2026-05-14T18:03:14.526770+00:00","generated_at":"2026-05-31T09:23:31.993235+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Arcutis Q2 product revenue $30.9M, up 547% YoY; net loss narrows to $52.3M","bullets":["ZORYVE franchise net product revenue $30.9M ($17.3M cream, $13.6M foam); 43% sequential growth.","Net loss $52.3M ($0.42/share) vs $71.0M loss in Q2 2023; cash $363.1M.","Entered co-promotion with Kowa Pharmaceuticals for primary care and pediatric promotion of ZORYVE.","Submitted sNDA for ZORYVE foam for scalp/body psoriasis; FDA approved cream 0.15% for atopic dermatitis.","Amended $200M term loan: rate reduced 150bps, maturity extended to June 2029, $100M prepay/re-draw option."],"urls":{"canonical":"https://secwatch.observer/filing/0001787306-24-000122","json":"https://secwatch.observer/filing/0001787306-24-000122.json","markdown":"https://secwatch.observer/filing/0001787306-24-000122.md","text":"https://secwatch.observer/filing/0001787306-24-000122.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1787306/000178730624000122/0001787306-24-000122-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1787306/000178730624000122/arqt-20240814.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-31T09:23:31.993235+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}